Thyroid cancer and lymphoma are connected through several distinct biological and clinical pathways, and the relationship runs in both directions. Survivors of thyroid cancer face an elevated risk of developing lymphoma later, partly because of the treatments used against their first cancer. Survivors of lymphoma, particularly those treated with radiation to the neck in childhood, face a strikingly elevated risk of thyroid cancer. And both cancers can even arise simultaneously in the same thyroid gland, often in people with a history of chronic autoimmune thyroid disease. The picture is more layered than a simple yes-or-no answer allows.
Thyroid Cancer Survivors and the Risk of Second Cancers
People who survive thyroid cancer have a modestly higher risk of developing a new, unrelated cancer compared to the general population. A large population-based study in Taiwan followed thyroid cancer survivors over roughly 135,000 person-years and found that the overall risk of a second primary cancer was about a third higher than expected. Lymphoma and leukemia were among the cancers that appeared at elevated rates, and the risk was steepest in the first five years after the thyroid cancer diagnosis, then dropped considerably over time.1Oxford Academic. Second primary malignancies following thyroid cancer: a population-based study in Taiwan This pattern of early elevated risk suggests that something about the initial cancer or its treatment, rather than just bad luck, is driving the association.
How Radioactive Iodine Treatment Raises Lymphoma Risk
The leading suspect for much of this increased risk is radioactive iodine therapy, the standard treatment for many differentiated thyroid cancers. Radioactive iodine is taken up by thyroid tissue and destroys residual cancer cells, but it also delivers radiation to the bone marrow and lymphatic tissue, which are the tissues where leukemias and lymphomas originate.
A nationwide study found that thyroid cancer patients treated with radioactive iodine had a significantly higher incidence of non-Hodgkin lymphoma compared to the general population, with a standardized incidence ratio of about 2.4. The risk climbed with cumulative dose: each additional 30 millicuries of radioactive iodine slightly increased the hazard for a second cancer, and patients who received cumulative doses above 150 millicuries had roughly a 30% higher overall cancer risk and a sixfold higher leukemia risk.2JNCI: Journal of the National Cancer Institute. Use of Radioactive Iodine for Thyroid Cancer and Risk for Second Primary Malignancy: A Nationwide Population-Based Study The concern is not confined to leukemia. A separate analysis looking at well-differentiated thyroid cancer patients found that radioactive iodine was tied to higher rates of both acute and chronic myeloid leukemia, even in patients whose tumors were classified as low or intermediate risk, meaning they might not have strictly needed the treatment.3PubMed Central. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer
Age at treatment also matters. A recent study that stratified risk by age group found that the specific type of blood cancer varied across age brackets. Adults aged 15 to 44 who received radioactive iodine had an elevated risk of hematologic cancers overall, with myeloma standing out. In the 45-to-64 group, the risk tilted toward non-Hodgkin lymphoma in the lymph nodes, roughly tripling. Patients 65 and older faced a heightened risk of acute myeloid leukemia.4JAMA Otolaryngology–Head & Neck Surgery. Age-Specific Risk of Second Primary Malignant Neoplasm After Radioactive Iodine Treatment for Differentiated Thyroid Cancer The fact that the risk profile shifts with age reinforces that radioactive iodine’s effects on the blood-forming system are real, not just a statistical artifact.
The Reverse Direction: Lymphoma Treatment and Thyroid Cancer
The link works the other way around too, and sometimes more dramatically. People treated for lymphoma, especially Hodgkin lymphoma with radiation to the neck and chest, face an elevated risk of developing thyroid cancer years or decades later. This is particularly pronounced in children and young adults, whose thyroid tissue is more vulnerable to radiation damage.
An international study of childhood cancer survivors found that after Hodgkin lymphoma, thyroid cancer was the most common second cancer, appearing at more than 50 times the expected rate. Even after childhood non-Hodgkin lymphoma, the thyroid cancer risk was roughly 40 times higher than in the general population.5JNCI: Journal of the National Cancer Institute. Risk of Second Malignant Neoplasms After Childhood Leukemia and Lymphoma: An International Study A study from the Childhood Cancer Survivor Study, following over 12,500 five-year childhood cancer survivors, quantified the dose-response curve for thyroid radiation: cancer risk rose linearly with dose up to about 20 Gy, where it peaked at roughly a 15-fold increase, then actually fell at higher doses, probably because very high radiation kills thyroid cells outright rather than just damaging them.6PubMed Central. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study
Among pediatric Hodgkin lymphoma survivors specifically, one cohort study found a nearly 28-fold increase in thyroid cancer risk compared to the general population after a median follow-up of 27 years. Women treated before age 10 had the highest hazard.7OncLive. Study Confirms Long-Term Risk of Secondary Cancers in Pediatric Hodgkin Lymphoma Survivors The latency period is long, often 15 to 25 years, which means a child treated for Hodgkin lymphoma at age 8 may develop thyroid cancer in their 30s. In adult patients treated after age 35, by contrast, no thyroid cancers were observed in one large cohort, suggesting that age at the time of radiation is the key modifier.8International Journal of Radiation Oncology, Biology, Physics. Long-Term Risk of Thyroid Cancer After Treatment for Hodgkin Lymphoma
Hashimoto’s Thyroiditis as the Bridge
Beyond treatment effects, there is a third pathway linking thyroid cancer and lymphoma that has nothing to do with radiation: chronic autoimmune inflammation, specifically Hashimoto’s thyroiditis. Hashimoto’s is the most common cause of hypothyroidism and involves the immune system chronically attacking thyroid tissue. That sustained immune activity creates fertile ground for both thyroid carcinoma and a rare entity called primary thyroid lymphoma.
Primary thyroid lymphoma accounts for roughly 5% of thyroid cancers and about 2% of lymphomas arising outside the lymph nodes.9PubMed Central. Primary thyroid lymphoma: a case series Nearly all of them are non-Hodgkin lymphomas of B-cell origin. The overwhelming majority arise in people with a history of Hashimoto’s thyroiditis, and multiple studies estimate that having Hashimoto’s raises the risk of primary thyroid lymphoma by 40 to 80 times.10PubMed Central. Thyroid B-Cell Lymphoma in the Background of Hashimoto’s Thyroiditis: A Case Report and Literature Review11PubMed Central. The Risk of Developing Lymphoma among Autoimmune Thyroid Disorder Patients: A Cross-Section Study The mechanism is thought to involve years of B-cell infiltration into the thyroid gland, creating an environment where those immune cells can accumulate mutations and eventually transform into lymphoma.
Hashimoto’s also raises the risk of thyroid carcinoma. Patients with the condition are roughly three times more likely to have thyroid cancer than those without it, a finding that has been replicated across multiple study designs.12PubMed Central. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway So Hashimoto’s acts as a shared risk factor, independently predisposing the same gland to both an epithelial cancer (thyroid carcinoma) and a blood cancer (lymphoma). This is one of the reasons the two cancers can occasionally appear side by side in the same thyroid.
When Both Cancers Show Up at Once
Case reports and small series document instances where thyroid carcinoma and lymphoma are found simultaneously in the same patient, sometimes in the same surgical specimen. In one well-documented case, a patient with longstanding Hashimoto’s thyroiditis was found to have extranodal marginal zone B-cell lymphoma (a type of MALT lymphoma) in one thyroid lobe and papillary thyroid carcinoma in the other.13PubMed. Co-occurrence of papillary thyroid carcinoma and primary lymphoma of the thyroid in a patient with long-standing Hashimoto’s thyroiditis A more extreme case involved a patient with three simultaneous cancers: medullary carcinoma in one lobe, papillary carcinoma in the other, and small lymphocytic lymphoma in the cervical lymph nodes.14PubMed Central. Simultaneous occurrence of papillary thyroid carcinoma, medullary thyroid carcinoma, and lymphoma: A case report
These simultaneous diagnoses are rare but not as rare as you might expect given the small numbers. A retrospective series at a single institution identified multiple cases of synchronous thyroid cancer and lymphoma, and the prognosis was actually encouraging: most patients with B-cell lymphoma survived over three years, and thyroid carcinoma did not recur in the majority. The exception was a patient with peripheral T-cell lymphoma, who survived only two months.15PubMed Central. Synchronous double primary lymphoma and thyroid cancer: A single-institution retrospective study Another series reported a 100% five-year survival rate among patients with concurrent papillary thyroid carcinoma and indolent B-cell lymphoma who received chemotherapy.16PubMed Central. Concurrent papillary thyroid carcinoma and incidental cervical lymph node indolent B cell non-Hodgkin lymphoma: clinicopathological features, outcomes, and potential relationships The good news is that when both cancers are caught, each one is typically treatable on its own terms.
The Subtypes That Arise in the Thyroid
Not all thyroid lymphomas are the same. In a single-center analysis of primary thyroid non-Hodgkin lymphomas, diffuse large B-cell lymphoma and MALT lymphoma accounted for nearly all cases, split roughly evenly. Only one case of T-cell lymphoma was detected.17PubMed Central. Clinicopathological analysis of primary thyroid non-Hodgkin lymphoma: a single-center study The distinction is clinically important because MALT lymphomas tend to be indolent and often remain confined to the thyroid, while diffuse large B-cell lymphomas are more aggressive and generally require systemic chemotherapy.
MALT lymphomas of the thyroid are the ones most directly tied to Hashimoto’s thyroiditis. They are thought to arise from the lymphoid tissue that accumulates in the gland during years of autoimmune inflammation, analogous to how MALT lymphomas of the stomach arise in the setting of chronic Helicobacter pylori infection. In some cases, a MALT lymphoma can transform into diffuse large B-cell lymphoma over time, which underscores why ongoing monitoring matters even for seemingly low-grade disease.
Shared Genetic Mutations
One of the more surprising findings in recent years is that thyroid lymphomas sometimes carry genetic mutations typically associated with thyroid carcinoma. The BRAF V600E mutation, which is practically a hallmark of papillary thyroid carcinoma, was found in one diffuse large B-cell lymphoma of the thyroid. Other BRAF mutations (D594G, K601N) and NRAS mutations (Q61K, Q61H) appeared in additional thyroid lymphomas. In total, about a quarter of diffuse large B-cell lymphomas of the thyroid in one study carried one of these mutations.18PubMed Central. Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas This overlap has practical implications. If a needle biopsy of a thyroid mass comes back positive for BRAF V600E, clinicians naturally think thyroid carcinoma. But a lymphoma is also in the differential, something worth keeping in mind especially if the clinical picture does not fit the usual carcinoma profile.
Diagnostic Challenges and Incidental Findings
Diagnosis is a real sticking point. Primary thyroid lymphoma can mimic thyroid carcinoma on imaging and physical exam. A rapidly growing thyroid mass in an older woman with Hashimoto’s disease could be either an aggressive thyroid carcinoma or a lymphoma, and the treatment is completely different. Fine-needle aspiration, the standard first-line test for thyroid nodules, catches lymphoma with a sensitivity of about 73% when combined with flow cytometry, but misses a meaningful fraction.19Journal of the American Society of Cytopathology. Multi-institutional study of fine-needle aspiration for thyroid lymphoma The cells from a lymphoma can look deceptively like chronic thyroiditis on a smear, so flow cytometry for clonality is often the key to distinguishing the two.
There is also a historical dimension to these diagnostic difficulties. Before modern immunohistochemistry became routine, some thyroid lymphomas were misclassified as anaplastic thyroid carcinomas, one of the deadliest forms of thyroid cancer. A study from the late 1980s reexamined 26 cases originally diagnosed as anaplastic thyroid carcinoma and reclassified three of them as lymphomas using immunostaining techniques.20Cancer. Anaplastic thyroid carcinoma. A clinical, histologic, and immunohistochemical study The practical consequence was enormous: those three patients had a treatable cancer that was being managed as if it were essentially untreatable.
On the imaging side, PET scans performed for lymphoma staging frequently pick up incidental thyroid findings. In a study of nearly 1,900 lymphoma patients who underwent PET or PET-CT, about 2.8% showed unexpected radiotracer uptake in the thyroid gland.21PubMed. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma Most of these turn out to be benign thyroiditis or incidental thyroid nodules, but a subset harbor thyroid cancers or involvement by the lymphoma itself.22PubMed. Lymphomas and thyroid: Bridging the gap A larger study of over 71,000 cancer patients who underwent PET-CT found that smaller nodules, higher metabolic activity, irregular margins on CT, and younger age all pointed toward a higher chance of malignancy among these incidental thyroid findings.23PubMed. Thyroid incidentalomas detected on (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in cancer patients: imaging clues for further evaluation For lymphoma patients who light up in the thyroid on a scan, the question of whether that signal represents their lymphoma, a separate thyroid cancer, or benign inflammation requires careful evaluation rather than assumption.
The Pediatric and Young Adult Picture
Children and young adults occupy a unique place in this story because their tissues are more radiation-sensitive and because the latency periods for second cancers extend across their long remaining lifespans. Among nearly 6,800 pediatric lymphoma survivors in one study, about 6% developed a second primary malignancy. Thyroid cancer and breast cancer were the most common, followed by hematologic cancers including leukemia and additional lymphomas.24PubMed Central. Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma The risk patterns differed between Hodgkin and non-Hodgkin lymphoma survivors, reflecting the different treatment protocols used for each.
What makes these numbers actionable is that they translate directly into screening recommendations. Childhood lymphoma survivors, especially those who received radiation to the neck, are typically advised to begin thyroid screening with physical exams and ultrasound starting five to ten years after treatment and continuing indefinitely. This is not a theoretical exercise: catching these thyroid cancers early, while they are small and confined, results in excellent cure rates. Without screening, the cancers may grow silently for years.
Circulating Tumor DNA and Emerging Monitoring Tools
For patients navigating both thyroid cancer and lymphoma, the question of how to monitor for recurrence or new disease without endless biopsies is a real practical concern. Circulating tumor DNA, tiny fragments of cancer-derived DNA detectable in a blood draw, is emerging as a tool for lymphoma monitoring. It allows clinicians to assess tumor burden, track treatment response, and detect residual disease without repeat tissue sampling.25PubMed Central. Circulating tumor DNA in lymphoma: technologies and applications The technology is still maturing and is not yet standard of care for thyroid cancer surveillance, but for lymphoma survivors who also need thyroid monitoring, blood-based assays could eventually simplify what is currently a burdensome surveillance schedule involving separate imaging modalities, blood tests, and clinical exams for each cancer.